
Remi Mahmoud

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4377223/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Immunomodulator Withdrawal From Anti-TNF Therapy Is Not Associated With Loss of Response in Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology, 2022, 20, 2577-2587.e6.	4.4	16
2	Letter: loss of response to anti‶NFα agents depends on treatment duration in patients with inflammatory bowel disease—authors' reply. Alimentary Pharmacology and Therapeutics, 2022, 55, 499-500.	3.7	2
3	Editorial: risk of loss of response to anti TNFα in patients with inflammatory bowel diseases – the longer the less? Authors' reply. Alimentary Pharmacology and Therapeutics, 2022, 55, 246-246.	3.7	0
4	Immunomodulator Withdrawal From Anti-TNF Therapy Needs A Careful Patient Selection – Authors' reply. Clinical Gastroenterology and Hepatology, 2022, , .	4.4	0
5	Continuation of Anti-TNF in Patients With Ulcerative Colitis in Remission Is Not Cost-effective Compared With Treatment Withdrawal: A Markov Model. Journal of Crohn's and Colitis, 2021, 15, 709-718.	1.3	6
6	Loss of response to anti‶NFα agents depends on treatment duration in patients with inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2021, 54, 1298-1308.	3.7	24
7	Surveillance and management of colorectal dysplasia and cancer in inflammatory bowel disease: Current practice and future perspectives. European Journal of Internal Medicine, 2021, 93, 35-41.	2.2	15
8	Editorial: missed opportunities to detect colorectal cancer in inflammatory bowel disease—getting to the root. Alimentary Pharmacology and Therapeutics, 2021, 53, 335-336.	3.7	3
9	Association Between Indefinite Dysplasia and Advanced Neoplasia in Patients With Inflammatory Bowel Diseases Undergoing Surveillance. Clinical Gastroenterology and Hepatology, 2020, 18, 1518-1527.e3.	4.4	26
10	No Association Between Pseudopolyps and Colorectal Neoplasia in Patients With Inflammatory Bowel Diseases. Gastroenterology, 2019, 156, 1333-1344.e3.	1.3	58
11	Reporting of patient characteristics and stratification factors in phase 3 trials investigating first-line systemic treatment of metastatic colorectal cancer: A systematic review. European Journal of Cancer, 2018 96 115-124	2.8	2